Showing results (1571-1580 of 1,711) with videos related to
Sort By:
Pageof 172
Journal of Cardiovascular Computed Tomography|December 27, 2021
2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines, Martha Gulati, Phillip D Levy, et al.Medrxiv : the Preprint Server for Health Sciences|May 11, 2021
Lipid-Modulating Agents for Prevention or Treatment of COVID-19 in Randomized TrialsAzita H Talasaz, Parham Sadeghipour, Maryam Aghakouchakzadeh, et al.The New England Journal of Medicine|November 13, 2018
Dapagliflozin and Cardiovascular Outcomes in Type 2 DiabetesStephen D Wiviott, Itamar Raz, Marc P Bonaca, et al.The New England Journal of Medicine|November 8, 2018
Alirocumab and Cardiovascular Outcomes after Acute Coronary SyndromeGregory G Schwartz, P Gabriel Steg, Michael Szarek, et al.European Heart Journal|January 23, 2017
Three, six, or twelve months of dual antiplatelet therapy after DES implantation in patients with or without acute coronary syndromes: an individual patient data pairwise and network meta-analysis of six randomized trials and 11 473 patientsTullio Palmerini, Diego Della Riva, Umberto Benedetto, et al.Journal of the American College of Cardiology|October 15, 2021
Investigating Lipid-Modulating Agents for Prevention or Treatment of COVID-19: JACC State-of-the-Art ReviewAzita H Talasaz, Parham Sadeghipour, Maryam Aghakouchakzadeh, et al.European Journal of Preventive Cardiology|July 23, 2026
Baseline Anemia and Short Dual Antiplatelet Therapy in High Bleeding Risk Patients Undergoing Percutaneous Coronary InterventionFrancesca Maria Di Muro, Samantha Sartori, Dominick J Angiolillo, et al.Circulation|March 19, 2019
Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial InfarctionRemo H M Furtado, Marc P Bonaca, Itamar Raz, et al.European Heart Journal|October 14, 2020
Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trialMichael Szarek, Vera A Bittner, Philip Aylward, et al.Circulation|November 1, 2017
International Expert Consensus on Switching Platelet P2Y12 Receptor-Inhibiting TherapiesDominick J Angiolillo, Fabiana Rollini, Robert F Storey, et al.Pageof 172